

DAFTAR PUSTAKA

1. Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. *Nat Rev Rheumatol*. 2021;17(9):515–532.
2. Kemenkes RI. Lupus Nefritis Indonesia. Published online 2017:1–7.
3. Fava A, Petri M. SLE: Diagnosis and Clinical Management. *Physiol Behav*. 2020;176(3):139–148.
4. Data Kunjungan Pasien SLE di Instalasi Rawat Jalan RSUD Raden Mattaher, 2019-2021.
5. Sumariyono, Kalim H, Setyohadi B, et al. Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. Perhimpunan Reumatologi Indonesia; 2019.
6. Emamikia S, Gentline C, Enman Y, Parodis I. How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study. *J Clin Med*. 2022;11(7):1857.
7. Albuquerque ES, Pinto L d. S, Neto VLM, Fragoso TS. Medication adherence in systemic lupus erythematosus during Brazilian COVID-19 pandemic. *Lupus*. 2022;31(2):221–227.
8. Irawati S, Prayitno A, Angel A, Safitri RH. Studi Pendahuluan Profil Penggunaan Obat dan Kepatuhan terhadap Pengobatan pada Pasien Lupus di Komunitas. *J Sains Farm Klin*. 2015;2(1):78.
9. Lestari RL, Nasution TH, Wibisono AH, Jannah M, Widiyanti UN, Dewi ES. Hubungan Tingkat Penerimaan diri dengan Tingkat Kepatuhan Minum Obat Pasien Lupus di Yayasan Kupu Parahita Indonesia. *Bul Penelit Kesehat*. 2021;49(4):215–222.
10. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update in the diagnosis and management of systemic lupus erythematosus. *Ann Rheum Dis*. 2021;80(1):14–25.

11. Bertsias G, Cervera R, Boumpas DT. Systemic Lupus Erythematosus: Pathogenesis and Clinical Features. EULAR; 2012.
12. Cava A La. Overview of the pathogenesis of systemic lupus erythematosus. In: Systemic Lupus Erythematosus. 2nd Ed. Elsevier Inc; 2020:69–75.
13. Maidhof W, Hilas O. Lupus: an overview of the disease and management options. P T. 2012;37(4):240–249.
14. Chaigne B, Chizzolini C, Perneger T, et al. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol. 2017;18(1):1–9.
15. Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med. 2016;16(5):481–485.
16. Teixeira FM. Diagnosing immune-mediated reactions to drugs. 2009;37(2):98–104.
17. Smith W. Adverse drug reactions. Aust J Gen Pract. 2013;42:12–16.
18. Dr. Rusli, Sp.FRS, APT. Farmasi Klinik. Badan Pengembangan dan Pemberdayaan Sumber Daya Manusia Kesehatan; 2018.
19. U.S food and drug administration. The Drug Development Process. FDA.
20. Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology. 2007;46(6):895–898.
21. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology. 2020;59(5):69–81.
22. Gast A, Mathes T. Medication adherence influencing factors (updated) overview of systematic reviews. Syst Rev. 2019;8(1):112.
23. Dr. Sonia Kim. Transcript: Medication Adherence. FDA.

24. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol*. 2012;73(5):691–705.
25. Lam WY, Fresco P. Medication Adherence Measures: An Overview. Giardini A, ed. *Biomed Res Int*. 2015;2015:217047.
26. Dew MA, Dabbs AD, Myaskovsky L, et al. Meta-Analysis of Medical Regimen Adherence Outcomes in Pediatric Solid Organ Transplantation. *Transplantation*. 2009;88(5).
27. Morisky, D. E., Green, L. W., & Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care*. 1986;24(1):67–74.
28. Sabaté E. Adherence to long-term therapies: evidence for action. World Health Organization; 2003.
29. Sheba SH dkk. Kepatuhan Minum Obat Pada Pasien Lupus Eritematosus Sistemik Drug Adherence Drug in Systemic Lupus Erythematosus Patients in Dr . Hasan Sadikin General Hospital Bandung. 2018;50(369):21–28.
30. Amalia R, Sasongko H, Kundarto W, Niruri R. The Analysis of the Factors affecting Medication Adherence in Patient with SLE (Systemic Lupus Erythematosus) at Yayasan Tittari Griya Kupu Solo. *Indian J Public Heal Res Dev*. 2019;10(3).
31. Rosyida L. Kepatuhan Pasien pada Penggunaan Obat Antidiabetes dengan Meode Pill-Count dan MMAS-8 di Puskesmas Kedurus Surabaya. *J Farm Komunitas*. 2015;2(2):36–41.
32. Arikunto S. *Prosedur Penelitian Suatu Pendekatan Praktek*. Rineka Cipta; 2013.
33. Defiia Anogra Riani. Validasi 8-Item Morisky Medication Adherence Scale Versi Indonesia Pada Pasien Hipertensi Dewasa Di Puskesmas Kabupaten Sleman Dan Kota Yogyakarta. Published online 2017.

34. Shin S. Drug utilization and therapy provision patterns by prescriber types among patients with systemic lupus erythematosus in Korea. *Patient Preference Adherence*. 2017;11:1779–1787.
35. Scofield RH, Bruner GR, Namjou B, et al. Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: Support for the notion of a gene-dose effect from the X chromosome. *Arthritis Rheum*. 2008;58(8):2511–2517.
36. Macejová Ž, Záriková M, Oetterová M. Systemic lupus erythematosus - disease impact on patients. *Cent Eur J Public Health*. 2013;21(3):171–173.
37. Pineau CA, Lee C, Ramsey-Goldman R, Clarke AE, Bernatsky S. The second hit: Comorbidities in systemic lupus erythematosus. *Fut Rheumatol*. 2007;2(5):497–506.
38. Sav A, King MA, Whitty JA, et al. Burden of treatment for chronic illness: a concept analysis and review of the literature. *Heal Expect an Int J public Particip Heal care Heal policy*. 2015;18(3):312–324.
39. Hansen RB, Simard JF, Faurschou M, Jacobsen S. Distinct patterns of comorbidity prior to diagnosis of incident systemic lupus erythematosus in the Danish population. *J Autoimmun*. 2021;123:102692.
40. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. *Rheumatology*. 2012;51(7):1145–1153.
41. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. *Arthritis Rheum Off J Am Coll Rheumatol*. 2000;43(8):1801–1808.
42. Karp I, Abrahamowicz M, Fortin PR, et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? *Arthritis Care Res (Hoboken)*. 2008;59(2):169–175.
43. Perricone C, Ceccarelli F, Spinelli FR, et al. Management of

- mycophenolate mofetil-induced acne in patients with Systemic Lupus Erythematosus: report of four cases and review of the literature. *Mediterr J Rheumatol*. 2018;29(4):217–220.
44. Du X, Chen H, Zhuang Y, Zhao Q, Shen B. Medication Adherence in Chinese Patients With Systemic Lupus Erythematosus. *JCR J Clin Rheumatol*. 2020;26(3).
 45. Semo-Oz R, Wagner-Weiner L, Edens C, et al. Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus. *Lupus*. 2022;31(12):1508–1515.
 46. Rahayu DS, Udiyono A, Saraswati LD. Hubungan Tingkat Pengetahuan dan Tingkat Kepatuhan Minum Obat dengan Tingkat Kekambuhan Lupus Eritematosus Sistemik. *J Epidemiol Kesehat Komunitas*. 2021;6(2):261–268.
 47. Eslami O, Norooznezhad AH, Movassaghi S, Naderi N, Rostamian A, Dormohammadi Toosi T. Investigating Adherence to Medication in Patients Diagnosed with Systemic Lupus Erythematosus: A Cross-Sectional Study in Iran. *Rheumatol Res*. 2020;5(1):27–32.
 48. Xie X, Yang H, Nie A, Chen H, Li J. Predictors of medication nonadherence in patients with systemic lupus erythematosus in Sichuan: A cross-sectional study. *Patient Prefer Adherence*. 2018;12:1505–1511.
 49. Mahmoud H, Abdel Hamid Hawash M, Abd Elmaksoud M. Factors Affecting Adherence of Medication for Patients with Systemic Lupus Erythematosus. *Egypt J Heal Care*. 2022;13(3):1–17.
 50. Fernandez-Lazaro CI, García-González JM, Adams DP, et al. Adherence to treatment and related factors among patients with chronic conditions in primary care: A cross-sectional study. *BMC Fam Pract*. 2019;20(1):1–12.